The market for the montelukast ingredient used to treat allergic rhinitis and asthma has contracted for two consecutive years.

The reduction is analyzed to be due to the combined effect of the US FDA’s side effect warning request for the ingredient in 2020 and the prolonged COVID-19 crisis. Industry eyes are on how the impurity issue that recently emerged would additionally affect the market.

◆Conflicting results by product… Singulair ↓ 32% vs Monterizine ↑ 15%

According to the industry research institution UBIST on the 25th, outpatient prescription sales of the allergic rhinitis and asthma treatment market for montelukast was ₩94.8 billion last year.